GlassScriptPhysician profile
Dan Scott Albrecht
NPI 1972592137
$720.58
in general payments reported to CMS, 2019-2025
16 companies · $213 in 2025
The $213 reported for 2025 was more than what 80% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.39 · 2021: $67.73 · 2022: $76.05 · 2023: $74.64 · 2024: $272 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536 · Education: $24.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.52 |
| Education | $24.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $148.64 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.18 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $99.56 | 2023-2025 | Entyvio |
| Merck Sharp & Dohme LLC | $51.39 | 2022-2024 | Dificid |
| Abbvie INC. | $40.13 | 2024-2025 | |
| Abbott Laboratories | $38.89 | 2023-2025 | I-Stat |
| Gilead Sciences, INC. | $34.48 | 2020-2021 | |
| Janssen Biotech, INC. | $29.79 | 2024 | Simponi, Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $25.42 | 2025 | Iqirvo |
| Celltrion USA INC. | $24.89 | 2024 | Zymfentra |
| Regeneron Healthcare Solutions, INC. | $21.50 | 2024 | Dupixent |
| Amgen INC. | $20.77 | 2021 | |
| Siemens Medical Solutions USA, INC. | $15.15 | 2024 | Atellica Ch 930 Analyzer |
| Phathom Pharmaceuticals, INC. | $15.12 | 2025 | Voquezna |
| Medline Industries LP | $14.00 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Albrecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.